Perrigo Company plc Accumulated Other Comprehensive Income
Perrigo Company plc (PRGO) had Accumulated Other Comprehensive Income of -$22.80 million as of 2026-06-27, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent › Accumulated Other Comprehensive Income (Loss), Net of Tax
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-05
- 2026-06-27: Accumulated Other Comprehensive Income (Loss), Net of Tax -$22.80M.
- 2026-03-28: Accumulated Other Comprehensive Income (Loss), Net of Tax -$3.00M.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $4.80M.
- 2025-09-27: Accumulated Other Comprehensive Income (Loss), Net of Tax $69.60M.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax | Accumulated Other Comprehensive Income (Loss), Net of Tax as first filed |
|---|---|---|
| 2026-06-27 | -$22.80M 10-Q · filed 2026-08-05 | |
| 2026-03-28 | -$3.00M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $4.80M 10-Q · filed 2026-08-05 | |
| 2025-09-27 | $69.60M 10-Q · filed 2025-11-05 | |
| 2025-06-28 | $75.00M 10-Q · filed 2025-08-06 | |
| 2025-03-29 | -$70.40M 10-Q · filed 2025-05-07 | |
| 2024-12-31 | -$162.40M 10-K · filed 2026-02-26 | |
| 2024-09-28 | $9.80M 10-Q · filed 2024-11-06 | |
| 2024-06-29 | -$54.20M 10-Q · filed 2024-08-02 | |
| 2024-03-30 | -$37.70M 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $10.70M 10-K · filed 2025-02-28 | |
| 2023-09-30 | -$78.10M 10-Q · filed 2023-11-07 | |
| 2023-07-01 | $19.90M 10-Q · filed 2023-08-08 | |
| 2023-04-01 | -$6.30M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | -$27.00M 10-K · filed 2024-02-27 | |
| 2022-10-01 | -$317.10M 10-Q · filed 2022-11-08 | |
| 2022-07-02 | -$146.80M 10-Q · filed 2022-08-09 | |
| 2022-04-02 | $15.00M 10-Q · filed 2022-05-11 | |
| 2021-12-31 | $35.50M 10-K · filed 2023-02-28 | |
| 2021-10-02 | $54.20M 10-Q · filed 2021-11-12 | |
| 2021-07-03 | $307.10M 10-Q · filed 2021-08-11 | |
| 2021-04-03 | $276.70M 10-Q · filed 2021-05-12 | |
| 2020-12-31 | $395.00M 10-K · filed 2022-03-01 | |
| 2020-09-26 | $203.70M 10-Q · filed 2020-11-05 | |
| 2020-06-27 | $120.70M 10-Q · filed 2020-08-05 | |
| 2020-03-28 | $35.90M 10-Q · filed 2020-05-05 | |
| 2019-12-31 | $139.40M 10-K · filed 2021-03-01 | |
| 2019-09-28 | $56.60M 10-Q · filed 2019-11-06 | |
| 2019-06-29 | $99.50M 10-Q · filed 2019-08-08 | |
| 2019-03-30 | $69.00M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $84.60M 10-K · filed 2020-02-27 | |
| 2018-09-29 | $143.20M 10-Q · filed 2018-11-08 | |
| 2018-06-30 | $155.00M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $324.30M 10-Q · filed 2018-05-08 | |
| 2017-12-31 | $253.10M 10-K · filed 2019-02-27 | |
| 2017-09-30 | $191.20M 10-Q · filed 2017-11-09 | |
| 2017-07-01 | $130.50M 10-Q · filed 2017-08-10 | |
| 2017-04-01 | -$26.30M 10-Q · filed 2017-05-30 | |
| 2016-12-31 | -$81.80M 10-K · filed 2018-03-01 | |
| 2016-10-01 | $71.50M 10-Q/A · filed 2017-05-23 | |
| 2016-07-02 | $30.70M 10-Q/A · filed 2017-05-22 | $31.30M 10-Q · filed 2016-08-10 |
| 2016-04-02 | $137.40M 10-Q/A · filed 2017-05-22 | $136.70M 10-Q · filed 2016-05-16 |
| 2015-12-31 | -$15.30M 10-K · filed 2018-03-01 | -$15.50M 10-KT · filed 2016-02-25 |
| 2015-09-26 | $65.20M 10-Q · filed 2015-11-02 | |
| 2015-06-27 | $103.50M 10-K · filed 2017-05-22 | $102.40M 10-K · filed 2015-08-13 |
| 2015-03-28 | -$19.00M 10-Q · filed 2015-04-29 | |
| 2014-12-27 | $7.40M 10-Q · filed 2015-02-05 | |
| 2014-09-27 | $74.30M 8-K · filed 2014-11-20 | |
| 2014-06-28 | $139.60M 10-K · filed 2017-05-22 | |
| 2014-03-29 | $130.30M 10-Q · filed 2014-05-07 | |
| 2013-12-28 | $114.60M 10-Q · filed 2014-05-07 | |
| 2013-09-28 | $104.30M 10-Q · filed 2014-02-06 | -$16.51M 10-Q · filed 2013-11-04 |
| 2013-06-29 | $77.00M 10-KT · filed 2016-02-25 | $0.00 10-Q · filed 2013-11-04 |
| 2012-06-30 | $39.40M 10-K · filed 2014-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |